You are about to action:

Object being modified by the action

Do you want to proceed?

Share Video Link

https://www.bitchute.com/video/6BOZsdko4IBY/

Click to copy, then share by pasting into your messages, comments, social media posts and websites.

Embed Video HTML

Click to copy, then add into your webpages so users can view and engage with this video from your site.

Share to Social Media

Share to social media by clicking on the quick share links.

Report Content

Reason

Please select the most appropriate reason from the list provided.

Note: For a more detailed description of each reason, see our Community Guidelines.

Additional Comments

Please add any additonal comments that will help with the assessment of your request.

Note: Copyright claims must contain all the items specified within the Copyright Policy.

Email Submissions

We also accept reports via email. Please see the Guidelines Enforcement Process for instructions on how to make a request via email.

Thank you for submitting your report

We will investigate and take the appropriate action.

Add to Playlist

JOHNSON & JOHNSON COLLABORATES WITH EVOTEC TO DISRUPT OUR CELL SIGNALS...

Next video playing soon

Click to cancel

Autoplay has been paused

Click to watch next video

First published at 19:07 UTC on June 29th, 2022.

#johnson
#pharma
#cell

The Kurgan Report

subscribers

BitChute Advertisement

This destruction of humans via "vaccines" and "therapeutics" is definitely a turf war!

From the article:
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very proud to enter into this collaboration…

This destruction of humans via "vaccines" and "therapeutics" is definitely a turf war!

From the article:
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very proud to enter into this collaboration to explore unique approaches to high potential cell surface drug targets with novel therapeutic modalities and to deliver and make innovative therapeutic options available to patients."

Besides research funding, Evotec is entitled to success-based research and commercial milestones up to approximately € 210 m per project as well as tiered royalties on products resulting from this collaboration.

Source:
https://www.accesswire.com/705018/Evotec-Enters-a-Drug-Discovery-Collaboration-with-Janssen

LESS